CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was i… Read more
CNS Pharmaceuticals Inc (CNSP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.219x
Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) has a cash flow conversion efficiency ratio of -0.219x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.17 Million) by net assets ($9.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CNS Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how CNS Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CNS Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CNS Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intan Baruprana Finance Tbk
JK:IBFN
|
-0.018x |
|
Plasticos Compuestos S.A.
MC:KOM
|
0.142x |
|
WesCan Energy Corp.
PINK:GPIPF
|
-0.176x |
|
Seasif Exploration Inc.
V:SAF
|
N/A |
|
CIRRUS LOGIC
MU:CRU
|
0.004x |
|
Fuse Group Holding Inc
OTCQB:FUST
|
0.049x |
|
CIRRUS LOGIC - Dusseldorf Stock Exchang
DU:CRU
|
0.004x |
|
MOJ S.A
WAR:MOJ
|
0.054x |
Annual Cash Flow Conversion Efficiency for CNS Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of CNS Pharmaceuticals Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.18 Million | $-17.11 Million | -2.771x | -186.84% |
| 2023-12-31 | $-4.43 Million | $-14.14 Million | 3.190x | +345.76% |
| 2022-12-31 | $8.13 Million | $-10.56 Million | -1.298x | +36.50% |
| 2021-12-31 | $6.62 Million | $-13.54 Million | -2.045x | -289.68% |
| 2020-12-31 | $13.95 Million | $-7.32 Million | -0.525x | -12.23% |
| 2019-12-31 | $7.60 Million | $-3.55 Million | -0.467x | -135.85% |
| 2018-12-31 | $-549.30K | $-716.38K | 1.304x | -31.96% |
| 2017-12-31 | $-58.53K | $-112.20K | 1.917x | -- |